Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

The U.S. Food and Drug Administration (FDA) announced the target action date of its review of the sNDA for VTAMA (tapinarof) cream, 1% has changed.

Long-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD) with upadacitinib is safe and effective ...

Parents of children with atopic dermatitis (AD, also called eczema) know that the allergic condition can mean a heightened ...

In the wake of the elimination diets, 38% of the parents reported no improvement in their child’s AD, 35% reported a 25% ...

The ADapt study assessed the efficacy and safety of EBGLYSS in individuals who had previously been treated with dupilumab.

The Phase III ECZTEND study reported that patients treated with Adbry demonstrated long term safety and efficacy for up to ...

Atopic dermatitis (eczema) is diagnosed by a healthcare provider based on a combination of a person's symptoms and medical history, as well as a physical exam. Laboratory tests are sometimes performed ...

Therapy for atopic dermatitis is multi-faceted and encompasses restoring the skin barrier function, using anti-inflammatory medications (topical or systemic), identifying and eliminating triggers ...

Treatment with the Janus kinase (JAK) inhibitor upadacitinib (Rinvoq) showed a favorable long-term benefit-risk profile ...

ChatGPT recommendations regarding atopic dermatitis (AD) often differ from AAAAI/ACAAI practice parameter recommendations.

Individuals who suffer from atopic dermatitis are three times more likely to develop anxiety, depression and sleep ...